Company
Eisai Co., Ltd /  Date Established : Dec 6. 1941

Head Office
4-6-10 Koishikawa, Bunkyo-hu, Tokyo 112-8088, Japan(Tel : 81-3-3817-3700)

Representatives
  • Haruo Naito,
    Representative Corporate Officer and CEO
  • Hideki Hayashi,
    Representative Corporate Officer, Corporate Planning & Strategy and CIO
  • Yutaka Tsuchiya,
    Representative Corporate Officer, Healthcare Policy and China Business
  • Hajime Shimizu,
    Representative Corporate Officer and CFO
  • Hideshi Honda,
    Representative Corporate Officer and Asia Region President
Capital
44,985 million Yen (As of March 31, 2014)


Sales
  • Consolidated : 600,363 million Yen
  • Non-Consolidated : 341,766 million Yen
  • (The year ended March 31, 2014)

Scope of Business
  • Manufacturing and marketing of prescription medicines and over-the-counter products

Employees
  • Consolidated: 10,419
  • Non-Consolidated : 4,003 (As of March 31, 2014)

Communication
Offices
64 Communication Offices in Japan (As of September 30, 2014)

Production Plants
  • Kawashima Plant (Gifu Prefecture)
  • Kashima Business Office (Ibaraki Prefecture)
  • Sannova Co., Ltd. (Gunma Prefecture)
  • Eisai Inc. North Carolina Plant (U.S.A.)
  • Eisai Manufacturing Ltd. (U.K.)
  • Eisai China Inc. Suzhou Plant (China)
  • Eisai Pharmatechnology & Manufacturing Pvt. Ltd. (India), etc.
Laboratories
  • Tsukuba Research Laboratories (Ibaraki Prefecture)
  • Kawashima Laboratory (Gifu Prefecture)
  • KAN Research Institute Inc. (Hyogo Prefecture)
  • Eisai Inc. Andover Research Institute (U.S.A.)
  • Morphotek, Inc. (U.S.A.)
  • H3 Biomedicine Inc. (U.S.A.)
  • Eisai Ltd. Hatfield Research Institute (U.K.), etc.

Overseas Sales
Offices
  • Eisai Inc. (U.S.A.)
  • Eisai Ltd. (U.K.)
  • Eisai GmbH (Germany)
  • Eisai S.A.S. (France)
  • Eisai China Inc. (China)
  • Eisai Korea Inc. (South Korea), etc.

맨위로